The Medical Technology Group has called for the NHS to adopt a single, nationally consistent definition of value in medical technology procurement.
The organisation argues that procurement decisions should reflect long-term patient outcomes, clinical benefit, and system efficiency rather than focusing too narrowly on upfront purchase price. A unified definition, developed with clinicians, patients, and industry, would reduce variation across procurement decisions and create clearer signals for suppliers.
The call follows warnings that some medical technology suppliers are withdrawing products or declining tenders where pricing does not cover the cost of supply. That creates a direct risk for patient access while placing additional pressure on the industrial base behind devices, diagnostics, implants, consumables, and associated technologies.
Healthcare procurement is difficult because the benefits of a technology often appear outside the purchasing department. A device may cost more at the point of purchase but reduce length of stay, lower complication rates, shorten procedure time, improve patient mobility, or ease pressure on clinical teams. When procurement frameworks measure only the immediate price, savings and benefits elsewhere in the system can be missed.
The problem has sharpened as the NHS tries to recover capacity, reduce waiting lists, and adopt more technology while managing tight budgets. Medical technology supports diagnostics, surgery, monitoring, rehabilitation, infection control, and chronic disease management. The procurement challenge is to measure clinical, operational, and economic value together, rather than treating technologies as interchangeable line items.
Manufacturers and suppliers carry a significant cost burden before any product reaches the NHS. Medical technologies must pass through design control, quality systems, regulatory compliance, clinical evidence, production validation, sterilisation, packaging, logistics, and post-market surveillance. Those requirements protect safety and reliability, but they also add cost that cannot be ignored indefinitely in tender pricing.
Controlled manufacturing capacity is already a strategic issue in regulated healthcare markets. Investment such as ESCATEC’s certification of its UK medtech electronics facility shows how suppliers are building quality systems, production controls, and transfer capacity for medical device OEMs. That type of investment depends on a market environment where value is recognised beyond the lowest compliant bid.
A national definition of value would not remove the need for cost discipline. The NHS must continue to secure value for money and protect transparent purchasing. The issue is that value for money in medical technology cannot be judged through purchase price alone. A product that improves throughput, reduces readmissions, or shifts care into less expensive settings may support system efficiency even when its unit cost is higher.
Consistency is equally important. Suppliers selling into the NHS often face variation between trusts, regions, frameworks, and evaluation processes. That can slow adoption, duplicate assessment, and make it harder for companies to plan production or support UK market entry. A clearer national value framework could reduce friction while giving manufacturers a more predictable route to demonstrate clinical and economic benefit.
The UK has placed medical technology inside a wider life sciences and industrial strategy, but procurement practice will determine whether innovation can scale. Research funding and accelerator programmes cannot compensate for a market that rewards short-term price above long-term performance. Supplier exits and tender withdrawals are not abstract commercial problems; they directly affect product availability, patient choice, and industrial resilience.
The debate will require balance between affordability, safety, evidence, competition, and public accountability. It will also require procurement teams to recognise that medical technology access is part of health system performance. Narrow purchasing decisions can carry hidden costs in clinical time, patient outcomes, supply continuity, and domestic manufacturing capability.
The Medical Technology Group’s proposal places procurement at the point where health policy and industrial policy meet. Medical technology is a regulated manufacturing sector as well as a healthcare input, and the resilience of that sector increasingly depends on whether value is measured across the whole system.
